Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001493152-21-019686 0001876315 XXXXXXXX LIVE 2 Common Stock, Par Value $0.01 Per Share 12/22/2025 false 0001857044 45339J105 Indaptus Therapeutics, Inc. c/o Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York NY 10019 Michael J. Newman (1) 858-492-0485 c/o Indaptus Therapeutics 3 Columbus Circle, 15th Floor New York NY 10019 0001876315 N Newman Michael James SC N X1 114589.00 963.00 114589.00 963.00 115552.00 N 5.4 IN This Amendment No. 2 to Schedule 13D amends and supplements the Schedule 13D originally filed with the Securities and Exchange Commission by the Reporting Person on August 13, 2021 (the "Original 13D"), as amended on October 26, 2021, relating to the common stock, par value $0.01 per share of Indaptus Therapeutics, Inc., a Delaware corporation ("Indaptus" or the "Company"). Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported on the Schedule 13D. Capitalized terms in this Amendment No. 2 shall have the meanings ascribed to them in the Schedule 13D. Common Stock, Par Value $0.01 Per Share Indaptus Therapeutics, Inc. c/o Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York NY 10019 As of the date of this report there are 2,101,163 shares of Indaptus common stock outstanding. Accordingly, Dr. Newman beneficially owned 5.4% of the outstanding shares of Indaptus common stock on the date of this Amendment No. 2. Dr. Newman has sole voting and dispositive power over 114,589 shares of Indaptus common stock registered in his name. In addition, Dr. Newman may be deemed to hold shared voting and dispositive power over 963 shares of Indaptus common stock registered in the name of his spouse. On December 23, 2025, Reporting Person was issued 52,204 shares of common stock in connection with entry into the Modification Agreement (defined below). Not applicable. Not applicable. Item 6 of the Original Schedule 13D is hereby amended and restated as follows: On December 22, 2025, Indaptus entered into a Securities Purchase Agreement (the "Purchase Agreement") with David E. Lazar, pursuant to which he agreed to purchase from the Company 300,000 shares of Series AA Convertible Preferred Stock and 700,000 shares of Series AAA Convertible Preferred Stock of the Company at a combined aggregate purchase price of $6.00 per share of Preferred Stock for aggregate gross proceeds of $6.0 million, subject to the terms and conditions of the Purchase Agreement. On December 22, 2025, in connection with the transactions contemplated by the Purchase Agreement, the Company entered into employment modification agreements with Reporting Person (the "Modification Agreements"). Pursuant to the terms of the Reporting Person's Modification Agreement, Reporting Person received an equity settlement payment 216,617 shares of Common Stock, calculated using the consolidated closing bid price of the Company's Common Stock on the day immediately preceding the date of the Modification Agreement. In connection with the signing of the Purchase Agreement, Reporting Person agreed to enter into a voting agreement, dated December 22, 2025 (the "Voting Agreement"), pursuant to which Reporting Person agreed, in his capacity as stockholder of the Company, following the Proxy Effective Date (as defined in the Voting Agreement), to vote all of his shares of Common Stock in favor of all proposals recommended by the board of directors at a special meeting of stockholders to be called for the purpose of securing certain stockholder approvals in connection with the Purchase Agreement. In addition, upon and following the Proxy Effective Date, Reporting Person agreed that, for a period one (1) year from the Proxy Effective Date, Reporting Person, nor any of his representatives acting on his behalf, will in any manner, directly or indirectly: (i) effect or seek, offer or propose (whether publicly or otherwise) to effect, or cause or participate in or in any way advise, assist or encourage any other person to effect or seek, offer or propose (whether publicly or otherwise) to effect or participate in, (a) any acquisition of any securities (or beneficial ownership thereof) or assets of the Company, or any rights to acquire any such securities (including derivative securities representing the right to vote or economic benefit of any such securities) or assets; (b) any tender or exchange offer, merger or other business combination involving the Company; (c) any recapitalization, restructuring, liquidation, dissolution or other extraordinary transaction with respect to the Company; or (d) any "solicitation" of "proxies" (as such terms are used in the proxy rules of the Securities and Exchange Commission) or consents to vote any voting securities of the Company; (ii) form, join or in any way participate in a "group" (as defined under the 1934 Act) with respect to any securities of the Company; (iii) otherwise act, alone or in concert with others, to seek to control or influence the management, board of directors or policies of the Company; (iv) take any action which might force the Company to make a public announcement regarding any of the types of matters set forth in (i) above; (v) enter into any discussions or arrangements with any third party with respect to any of the foregoing; or (vi) request that the Company (or its directors, officers, employees or agents) amend or waive any provision of this paragraph (including clause (vi)). The foregoing description of the Voting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Voting Agreement, the form of which is filed as an exhibit hereto and is incorporated by reference herein. Exhibit 1. Form of Voting Agreement (incorporated by reference to Exhibit 10.7 of the Company's Current Report on Form 8-K filed with the SEC on December 22, 2025) Newman Michael James /s/ Michael J. Newman Michael J. Newman 12/30/2025